Abstract
Purpose Cytomegalovirus retinitis (CMVR) has been the most common cause of visual loss in AIDS patients. We investigate whether the pattern of disease has changed since the introduction of triple therapy.
Methods We reviewed the records of all patients with CMVR in one teaching hospital HIV unit over a 2 year period (n = 24). This included the ophthalmic and systemic findings, HIV and CMV treatment, survival after diagnosis and CD4 results.
Results There has been a marked decrease in the number of patients developing new CMVR: from 21 eyes (15 patients) to 4 eyes (4 patients) in two consecutive 12 month periods between January 1996 and December 1997, coinciding with the introduction of triple therapy in October 1996. Median survival has increased from 376 days in the deceased patients to 598 days in the survivors on triple therapy. Median time to CMVR relapse has lengthened from 79 to 179 days in the triple therapy cohort. The pattern of ocular morbidity in the 11 eyes of the 7 surviving patients is also changing, with no new zone 1 disease, and a marked rise in the incidence of uveitis, maculopathy and cataracts.
Conclusion Results suggest that triple therapy is associated with an increase in survival, a decrease in CMVR relapse and changes in ocular features. This transition has implications for current screening and treatment protocols.
Similar content being viewed by others
Article PDF
References
Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in an era of Pneumocystis prophylaxis. Multicenter AIDS cohort study. N Engl J Med 1993;329:1922–6.
Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trial Group. Foscarnet-ganciclovir cytomegalovirus retinitis trial. 4. Visual outcomes. Ophthalmology 1994;101:1250–61.
Mouton Y, Alfandari S, Vallette M, et al. Impact of protease inhibitors on AIDS defining events and hospitalisations in 10 French AIDS referral centres. AIDS 1997;11:101–5.
Rahhal FM, Arevalo JF, Munguia D, et al Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology 1996;103:1078–83.
Banker AS, Revalo JF, Munguia D, et al. Intraocular pressure and aqueous humour dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis. Am J Ophthalmol 1997;124:168–80.
Davis JL, Taskinhuna I, Freeman WR, Weinberg DV, Fiever WJ, Leonard RE . Iritis and hypotony after treatment with intravenous cidovir for CMV retinitis. Arch Ophthalmol 1997;115:733–7.
Bainbridge JWB, Raina J, Shah S . Anterior uveitis associated with CMV retinitis in AIDS: a review. Invest Ophthalmol Vis Sci (ARVO Suppl) 1998;39:S134.
Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trial Group. Foscarnet-ganciclovir cytomegalovirus retinitis trial. 5. Clinical features of cytomegalovirus retinitis at diagnosis. Am J Ophthalmol 1997;124:141–57.
Nussenblatt RB, Lane HC . Human immunodeficiency virus disease: changing patterns of ocular inflammation. Am J Ophthalmol 1998;125:374–82.
Magone MT, Nussenblatt RB, Whitcup SM . Elevation of laser flare photometry in patients with cytomegalovirus retinitis and AIDS. Am J Ophthalmol 1997;124:190–8.
Kuo IC, Kapusta MA, Rao NA . Vitritis as the primary manifestation of ocular syphilis in patients with HIV infection. Am J Ophthalmol 1998;125:306–11.
Margolis TP, Milner MS, Shama A, Hodge W, Seiff S . Herpes zoster ophthalmicus in patients with human immunodeficiency virus infection. Am J Ophthalmol 1998;125:285–91.
Silverstein BE, Smith JH, Sykes SO, et al. Cystoid macular oedema associated with cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1998;125:412–5.
Alder ME, Johnson DW, Burman WJ, Johnson SC . Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis. Ophthalmology 1998;105:651–7.
Bloom PA, Sandy CJ, Migdal C, et al. Visual prognosis of AIDS patients with cytomegalovirus retinitis. Eye 1995;9:697–702.
Jabs DA, Bartlett JG . AIDS and ophthalmology: a period of transition. Am J Ophthalmol 1997;124:227–33.
Gallant J, Moore D, Richman D, et al. Incidence and natural history of CMV disease in patients with advanced HIV disease. J Infect Dis 1992;166:1223–7.
Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease. Science 1997;277:112–7.
Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443–5.
Seigner SW, Holland GN, Stemien MJ, Craber M, Robinson CA, Hubbard L . The relationship between CMVR activity at the start of maintenance therapy and the time to progression. Invest Ophthalmol Vis Sci (ARVO Suppl) 1997;38:S915.
Reed JB, Schwab IR, Gordon J, Morse LS . Regression of cytomegalovirus retinitis associated with protease inhibitor treatment in patients with AIDS. Am J Ophthalmol 1997;124:199–205.
Vrabec TR, Baldassano VF, Whitcup SM . Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4 counts. Ophthalmology 1998;105:1259–64.
Studies of Ocular Complications of AIDS Research group in collaboration with the AIDS Clinical Trial Group. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomised cytomegalovirus retinitis trial. Arch Intern Med 1995;155:65–74.
Zegans ME, Watton RC, Holland GN, et al Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998;125:292–300.
Author information
Authors and Affiliations
Additional information
Presented as a paper at the Tenth Anniversary Congress of the Royal College of Ophthalmologists, Glasgow, 1998
Rights and permissions
About this article
Cite this article
Lee, V., Subak-Sharpe, I., Shah, S. et al. Changing trends in cytomegalovirus retinitis with triple therapy. Eye 13, 59–64 (1999). https://doi.org/10.1038/eye.1999.12
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/eye.1999.12